EDUCATION

Undergraduate Degree

  • Massachusetts Institute of Technology , Cambridge , MA

Graduate Degree

  • University of Texas Southwestern Medical School at Dallas , Dallas , TX

Medical School

  • University of Texas Southwestern Medical Center Medical School - University of Texas Southwestern Medical , Dallas , TX

Internship

Pediatrics
  • Babies and Children's Hospital, College of Physicians and Surgeons, Columbia University Medical Center , New York , NY

Residency

Pediatrics
  • Babies and Children's Hospital, College of Physicians & Surgeons, Columbia University Medical Center , New York , NY

Fellowship

Pediatric Hematology -Oncology
  • Boston Children's Hospita/Dana-Farber Cancer Institute , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Hematology and Oncology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10; 4(21):5414-5424. View abstract
  2. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020 06 09; 4(11):2536-2547. View abstract
  3. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020 11; 55(11):2160-2169. View abstract
  4. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 12 26; 134(26):2361-2368. View abstract
  5. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View abstract
  6. Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 07; 54(7):1158-1160. View abstract
  7. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2019 02; 25(2):301-306. View abstract
  8. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biol Blood Marrow Transplant. 2018 10; 24(10):2040-2046. View abstract
  9. Diffuse pityriasiform eruption in a pediatric patient after bone marrow transplantation. Pediatr Dermatol. 2018 Mar; 35(2):246-247. View abstract
  10. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018 02 15; 124(4):816-825. View abstract
  11. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1). View abstract
  12. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. J Pediatr Hematol Oncol. 2016 11; 38(8):610-614. View abstract
  13. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016 07; 22(7):1275-1283. View abstract
  14. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. Photomed Laser Surg. 2016 Apr; 34(4):178-84. View abstract
  15. Pediatric hematopoietic cell transplantation. J Pediatr Intensive Care. 2014 Sep; 3(3):91-101. View abstract
  16. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1013-23. View abstract
  17. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. Am J Infect Control. 2014 May; 42(5):485-9. View abstract
  18. Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. J Pediatr Hematol Oncol. 2014 Apr; 36(3):224-7. View abstract
  19. Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors. Development. 2010 Jun; 137(11):1907-17. View abstract
  20. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol. 2006 Sep; 26(18):7005-15. View abstract
  21. Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem. 2005 Jun 24; 280(25):23593-8. View abstract
  22. Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood. 2005 Feb 01; 105(3):1003-9. View abstract
  23. Extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with cardiomyopathy and hemophilia A. Intensive Care Med. 2003 Jun; 29(6):985-988. View abstract
  24. RNA turnover and the control of mitochondrial gene expression. Trends Biochem Sci. 1996 Oct; 21(10):392-6. View abstract
  25. The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity. Cell. 1996 Jan 26; 84(2):199-209. View abstract
  26. The yeast nuclear gene suv3 affecting mitochondrial post-transcriptional processes encodes a putative ATP-dependent RNA helicase. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):6813-7. View abstract